On July 1, the FDA expanded the label for Casgevy to include children as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia. Casgevy is the first therapy approved anywhere in the world that uses CRISPR/Cas9 gene editing. It was originally cleared in December 2023 for patients twelve and older. The expanded label adds approximately 5,500 pediatric patients to the eligible population in the United States. Vertex Pharmaceuticals, which developed the therapy with CRISPR Therapeutics, saw its stock rise six percent on the announcement.
The science is elegant. Sickle cell disease is caused by a single amino acid substitution: valine replaces glutamic acid at position six of the beta-globin chain. That one swap causes hemoglobin molecules to polymerize under low-oxygen conditions, deforming red blood cells into the rigid crescents that block capillaries, destroy tissue, and kill patients decades before their time. The disease has been understood at the molecular level since Linus Pauling described it in 1949. It took seventy-four years to get a gene therapy approved.
Casgevy does not fix the sickle mutation directly. It uses a bank shot. CRISPR/Cas9 makes a precise cut in the erythroid-specific enhancer region of a gene called BCL11A, which normally suppresses fetal hemoglobin production after birth. With BCL11A silenced, the patient's bone marrow begins producing fetal hemoglobin again. Fetal hemoglobin cannot sickle because it lacks the valine substitution entirely. In clinical trials, fetal hemoglobin reached 43.9 percent of total hemoglobin within six months and held that level through at least two years of follow-up. The sickle crises stopped.
That is the revolutionary part. It works. The part that should disturb anyone paying attention is what happens before the edit.
Before Casgevy can be infused, the patient's existing bone marrow must be destroyed to make room for the edited cells. This requires myeloablative conditioning with busulfan, an alkylating chemotherapy agent synthesized in 1953 and in clinical use since 1959. Busulfan cross-links DNA strands throughout the bone marrow, killing hematopoietic stem cells indiscriminately. It is not targeted. It is not precise. It is the pharmacological equivalent of clear-cutting a forest so you can plant a single tree. The conditioning protocol takes approximately four days. The patient spends weeks in isolation afterward while the edited cells engraft and the immune system rebuilds.
Among the cells busulfan destroys are the precursors to eggs and sperm. For post-pubertal patients, the solution is straightforward: bank gametes before treatment. For a two-year-old, there is nothing to bank. Ovarian tissue cryopreservation exists experimentally but is not standard of care. Testicular tissue banking is investigational. The practical reality is that a child treated at age two with Casgevy will be permanently infertile, and no one asked them.
This is the trade the FDA just expanded to toddlers. It is not a hidden trade. The label says it plainly. Fertility counseling is required. The parents decide. But the asymmetry is structural: the benefit is immediate and measurable, the cost is latent and irreversible, and the person bearing the cost cannot participate in the decision. The child will learn what was chosen for them at roughly the same age they would otherwise learn what sickle cell disease takes from them.
The economics frame the same tension differently. Casgevy costs $2.2 million per patient. Lifetime medical costs for privately insured patients with sickle cell disease average $1.7 million. For the most severe Medicaid enrollees, annual costs approach $200,000. The cure is not cheap, but neither is the disease. By any standard actuarial calculation, a one-time payment that eliminates decades of hospitalizations, transfusions, and opioid management is cost-effective. The Congressional Budget Office has begun modeling how expanded gene therapy access would affect the federal budget. The math works.
But the math does not explain the bottleneck. In the first quarter of 2026, Casgevy generated $43 million in revenue. More than 500 patients have started treatment globally since the December 2023 approval. The eligible population in the United States alone is approximately 20,000 patients with severe sickle cell disease and another 1,500 with transfusion-dependent beta thalassemia. At $2.2 million per treatment, the addressable market exceeds $40 billion. Vertex has captured roughly one-tenth of one percent of it.
The constraint is not demand. It is not price, though $2.2 million is not trivial. It is not skepticism about the science. The constraints are physical. Myeloablative conditioning requires inpatient hospitalization at an authorized treatment center with the capacity to manage a patient through weeks of immune suppression. The patient journey from evaluation to infusion can take up to a year. Geographic access is uneven. Patient hesitation and the complexity of the conditioning regimen compound the delay. More than 75 such centers are activated across the United States. Each can handle only a handful of conditioning protocols at a time. The gene therapy revolution is throttled by hospital bed availability for a 1959 chemotherapy regimen.
This is why the real race is not between Casgevy and its competitors. Bluebird Bio's Lyfgenia, the only other approved gene therapy for sickle cell disease, requires the same myeloablative conditioning. The real race is to eliminate conditioning entirely. Researchers at Stanford have demonstrated antibody-drug conjugates targeting CD117 on hematopoietic stem cells, achieving what they call fertility-preserving myeloablative conditioning in rhesus macaques. Beam Therapeutics and several academic groups are pursuing non-genotoxic conditioning approaches. Whoever solves this problem does not merely improve the patient experience. They remove the physical infrastructure constraint that limits the market to a few hundred patients per year.
Vertex trades at $528 with a $134 billion market cap. CRISPR Therapeutics, which receives a 40 percent profit share on Casgevy, trades at $62 with a $6 billion market cap. Vertex's full-year guidance includes $500 million or more from non-cystic-fibrosis products, a category that includes both Casgevy and Journavx, its non-opioid pain drug. The $43 million quarterly run rate for Casgevy implies that Vertex expects acceleration in the second half, driven by reimbursement progress in international markets and the pediatric label expansion.
The investment question is not whether CRISPR gene therapy works. It works. The question is whether the delivery infrastructure can scale before the next generation of therapies eliminates the conditioning requirement that constrains it. If non-myeloablative conditioning succeeds, the addressable market for gene therapy expands by an order of magnitude overnight. If it does not, gene therapy remains a boutique intervention, curing hundreds per year in a population of tens of thousands, limited not by the science but by the logistics of the preparation the science requires.
The most advanced tool in medicine still depends on the crudest step in medicine. The edit is a single cut at one enhancer in three billion base pairs. The conditioning is four days of a drug that destroys everything it touches. One is 2023 technology. The other is 1959 technology. The bottleneck was never the gene therapy. It was always the conditioning.